Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Respiratory Journal

• Publication date

  2010-06-04

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1183/09031936.00028009PMID 20525716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment.

  2009influential reference
• Hypoxia-driven mechanisms in lung biology and disease: a new review series of the ERS Lung Science Conference

  2008cited by this paper
• Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusion

  2008cited by this paper
• Prostacyclin therapies for the treatment of pulmonary arterial hypertension

  2008cited by this paper
• Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function.

  2007influential reference
• Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide.

  2007cited by this paper
• Diverse Contribution of Bone Marrow-Derived Cells to Vascular Remodeling Associated With Pulmonary Arterial Hypertension and Arterial Neointimal Formation

  2007cited by this paper
• Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts.

  2006cited by this paper
• The role of CCL12 in the recruitment of fibrocytes and lung fibrosis.

  2006cited by this paper
• Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.

  2006cited by this paper
• Treprostinil in Advanced Experimental Pulmonary Hypertension: Beneficial Outcome Without Reversed Pulmonary Vascular Remodeling

  2006cited by this paper
• Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis

  2006influential reference
• Pulmonary arterial hypertension

  2006cited by this paper
• Role of the adventitia in pulmonary vascular remodeling.

  2006cited by this paper
• Hypoxia- and non-hypoxia-related pulmonary hypertension - established and new therapies.

  2006cited by this paper
• Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms.

  2006cited by this paper
• Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage.

  2006influential reference
• Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension.

  2005influential reference
• CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury.

  2005influential reference
• Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension

  2005cited by this paper
• Reversal of experimental pulmonary hypertension by PDGF inhibition.

  2005cited by this paper
• Bone marrow-derived progenitor cells in pulmonary fibrosis.

  2004influential reference
• Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.

  2004influential reference
• Circulating fibrocytes: collagen-secreting cells of the peripheral blood.

  2004cited by this paper
• Pharmacokinetics of Treprostinil Sodium Administered by 28‐Day Chronic Continuous Subcutaneous Infusion

  2004cited by this paper
• Absolute Bioavailability and Pharmacokinetics of Treprostinil Sodium Administered by Acute Subcutaneous Infusion

  2004cited by this paper
• Pharmacokinetics and Steady-State Bioequivalence of Treprostinil Sodium (Remodulin®) Administered by the Intravenous and Subcutaneous Route to Normal Volunteers

  2004cited by this paper
• Identification of Circulating Fibrocytes as Precursors of Bronchial Myofibroblasts in Asthma1

  2003cited by this paper
• Nephrogenic fibrosing dermopathy: suspect identified, motive unclear.

  2003cited by this paper
• Circulating Vascular Progenitor Cells Do Not Contribute to Compensatory Lung Growth

  2003cited by this paper
• CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension

  2002cited by this paper
• Chemokine RANTES in severe pulmonary arterial hypertension.

  2002cited by this paper
• Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.

  2002cited by this paper
• The Prostacyclin Analogue Treprostinil Blocks NFκB Nuclear Translocation in Human Alveolar Macrophages*

  2002cited by this paper
• Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats.

  2002cited by this paper
• CX(3)C chemokine fractalkine in pulmonary arterial hypertension.

  2002cited by this paper
• Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell.

  2001cited by this paper
• Chronic airway infection leads to angiogenesis in the pulmonary circulation.

  2001cited by this paper
• Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo

  2001cited by this paper
• Physiologic basis for the treatment of pulmonary hypertension.

  2001cited by this paper
• Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites1

  2001cited by this paper
• Primary pulmonary hypertension: a vascular biology and translational research "Work in progress".

  2000cited by this paper
• Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

  1999cited by this paper
• Evidence for circulating bone marrow-derived endothelial cells.

  1998cited by this paper
• ‘Green mice’ as a source of ubiquitous green cells

  1997cited by this paper
• Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair

  1994cited by this paper
• CD34+ spindle-shaped cells selectively disappear from the skin lesion of scleroderma.

  1994cited by this paper
• Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.

  1994cited by this paper

• Targeting IL‐11 to reduce fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension‐associated lung fibrosis

  2024cites this paper
• The percentage of circulating fibrocytes is associated with increased morbidity of pulmonary hypertension in patients on hemodialysis

  2023cites this paper
• Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model

  2023cites this paper
• Single-Cell Transcriptome Profiles Reveal Fibrocytes as Potential Targets of Cell Therapies for Abdominal Aortic Aneurysm

  2021cites this paper
• Fibrocytes in early and long-standing rheumatoid arthritis: a 6-month trial with repeated synovial biopsy, imaging and lung function test

  2021cites this paper
• Niacin Attenuates Pulmonary Hypertension Through H-PGDS in Macrophages

  2020cites this paper
• Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model

  2020cites this paper
• Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.

  2020cites this paper
• Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice

  2019influential citation
• The Role of G Protein-Coupled Receptors in the Right Ventricle in Pulmonary Hypertension

  2018cites this paper
• A Twist on Pulmonary Vascular Remodeling: Endothelial to Mesenchymal Transition?

  2018cites this paper
• Resident cell lineages are preserved in pulmonary vascular remodeling

  2018cites this paper
• Efficacy of treprostinil in the SU5416‐hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling

  2018cites this paper
• The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension

  2017cites this paper
• Mechanisms of right heart disease in pulmonary hypertension (2017 Grover Conference Series)

  2017cites this paper
• The influence of sex on the in vivo and in vitro effects of treprostinil in pulmonary arterial hypertension

  2017cites this paper
• Versican Accumulates in Vascular Lesions in Pulmonary Arterial Hypertension

  2016cites this paper
• Therapeutic potential of adipose stem cell‐derived conditioned medium against pulmonary hypertension and lung fibrosis

  2016cites this paper
• From Here to There, Progenitor Cells and Stem Cells Are Everywhere in Lung Vascular Remodeling

  2016cites this paper
• Reconciling paradigms of abnormal pulmonary blood flow and quasi-malignant cellular alterations in pulmonary arterial hypertension.

  2016cites this paper
• Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells

  2015cites this paper
• Fibrocytes and Pulmonary Vascular Remodeling: The Good, the Bad, and the Progenitors

  2015cites this paper
• Circulating Biomarkers in Pulmonary Arterial Hypertension

  2015cites this paper
• Serum levels of tumor necrosis factor-related apoptosis-inducing ligand correlate with the severity of pulmonary hypertension.

  2015cites this paper
• CXCR4 Inhibition Ameliorates Severe Obliterative Pulmonary Hypertension and Accumulation of C-Kit+ Cells in Rats

  2014cites this paper
• Adult Lung Stem Cells

  2014cites this paper
• Bone Marrow–Derived Vascular Modulatory Cells in Pulmonary Arterial Hypertension

  2013cites this paper
• Vascular Repair and Regeneration as a Therapeutic Target for Pulmonary Arterial Hypertension

  2013cites this paper
• In vitro processing of human bone marrow derived mesenchymal stem cells to enhance delivery in liver disease

  2013cites this paper
• Proteomic Analysis Identifies Translationally Controlled Tumor Protein as a Potential Novel Mediator of Occlusive Vascular Remodeling in Pulmonary Arterial Hypertension

  2013cites this paper
• Artificial lung as an alternative to mechanical ventilation in COPD exacerbation

  2012cites this paper
• Pressure overload induces early morphological changes in the heart.

  2012cites this paper
• Genetically modified endothelial progenitor cells in the therapy of cardiovascular disease and pulmonary hypertension.

  2012cites this paper
• Fibrocytes in chronic lung disease--facts and controversies.

  2012cites this paper
• Chapter 9 – Role of Stem Cells in Neonatal Lung Injury

  2012cites this paper
• Circulating fibrocytes and pulmonary arterial hypertension

  2012cites this paper
• The role of collagen synthesis in ventricular and vascular adaptation to hypoxic pulmonary hypertension.

  2012cites this paper
• Peroxisome proliferator-activated receptor-β/δ, the acute signaling factor in prostacyclin-induced pulmonary vasodilation.

  2012cites this paper
• Identification of functional progenitor cells in the pulmonary vasculature

  2012cites this paper
• Rôle des progéniteurs dans l'hypertension artérielle pulmonaire humaine et expérimentale

  2011cites this paper
• Treprostinil inhibits the adhesion and differentiation of fibrocytes via the cyclic adenosine monophosphate-dependent and Ras-proximate protein-dependent inactivation of extracellular regulated kinase.

  2011cites this paper
• Circulating fibrocytes are increased in children and young adults with pulmonary hypertension

  2011cites this paper
• Fibrocytes: emerging effector cells in chronic inflammation

  2011cites this paper
• Measuring right ventricular function in the normal and hypertensive mouse hearts using admittance-derived pressure-volume loops.

  2010cites this paper
• Fibrocytes: potential new therapeutic targets for pulmonary hypertension?

  2010cites this paper